{"description":"Data of adverse events or adverse drug reactions were not collected as part of the study database.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":276,"description":"Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Multiple Myeloma (MM) Participants"}],"frequencyThreshold":"0","timeFrame":"From enrollment on 26 July 2017 to last date of assessment 30 January 2019 (Up to 1.5 years)"}